Nabriva Therapeutics PLC – (NASDAQ:NBRV) – Stock analysts at Wedbush increased their Q2 2019 earnings per share estimates for shares of Nabriva Therapeutics in a research note issued on Tuesday, May 14th. Wedbush analyst R. Driscoll now forecasts that the biotechnology company will earn ($0.33) per share for the quarter, up from their previous estimate of ($0.34). Wedbush also issued estimates for Nabriva Therapeutics’ Q3 2019 earnings at ($0.25) EPS, FY2019 earnings at ($1.14) EPS, FY2020 earnings at ($1.13) EPS, FY2021 earnings at ($0.73) EPS, FY2022 earnings at ($0.30) EPS and FY2023 earnings at $0.37 EPS.
Nabriva Therapeutics (NASDAQ:NBRV) last issued its earnings results on Friday, May 10th. The biotechnology company reported ($0.29) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.03. The company had revenue of $1.70 million for the quarter, compared to the consensus estimate of $0.56 million. Nabriva Therapeutics had a negative return on equity of 119.75% and a negative net margin of 3,194.72%.
NASDAQ:NBRV opened at $2.58 on Friday. Nabriva Therapeutics has a 52 week low of $1.12 and a 52 week high of $6.05. The company has a market capitalization of $1.80 billion, a P/E ratio of -1.58 and a beta of 2.42. The company has a debt-to-equity ratio of 0.40, a quick ratio of 6.11 and a current ratio of 5.55.
Institutional investors have recently made changes to their positions in the business. Parametric Portfolio Associates LLC boosted its position in Nabriva Therapeutics by 82.2% during the first quarter. Parametric Portfolio Associates LLC now owns 18,616 shares of the biotechnology company’s stock worth $45,000 after purchasing an additional 8,396 shares during the period. Jane Street Group LLC bought a new stake in Nabriva Therapeutics during the fourth quarter worth approximately $29,000. HRT Financial LLC bought a new stake in Nabriva Therapeutics during the fourth quarter worth approximately $31,000. Two Sigma Advisers LP bought a new stake in Nabriva Therapeutics during the fourth quarter worth approximately $37,000. Finally, Paloma Partners Management Co bought a new stake in Nabriva Therapeutics during the fourth quarter worth approximately $54,000. 4.61% of the stock is owned by hedge funds and other institutional investors.
About Nabriva Therapeutics
Nabriva Therapeutics plc, a clinical stage biopharmaceutical company, engages in the research and development of anti-infective agents to treat infections in humans. The company focuses on the pleuromutilin class of antibiotics. Its lead product candidate is lefamulin, which is in Phase III clinical trials in intravenous and oral formulations for the treatment of community-acquired bacterial pneumonia; and has completed Phase II clinical trials for the treatment of acute bacterial skin and skin structure infection.
Read More: How to Invest in a Bull Market
Receive News & Ratings for Nabriva Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.